ESR1 and breast cancer: Indeed, ERα is the key driver of breast tumorigenesis in ~75% of cases, and, at the same time, higher ERα load is often considered as predicting better prognosis in the general population of systemically-treated ER + BC patients, which is typically explained by the ability to effectively target ERα by existing hormonal therapy.